Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.

Koster BD, de Jong TD, van den Hout MFCM, Sluijter BJR, Vuylsteke RJCLM, Molenkamp BG, Vosslamber S, van den Tol MP, van den Eertwegh AJM, de Gruijl TD.

Oncoimmunology. 2019 Dec 26;9(1):1708066. doi: 10.1080/2162402X.2019.1708066. eCollection 2020.

2.

Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.

Koster BD, van den Hout MFCM, Sluijter BJR, Molenkamp BG, Vuylsteke RJCLM, Baars A, van Leeuwen PAM, Scheper RJ, Petrousjka van den Tol M, van den Eertwegh AJM, de Gruijl TD.

Clin Cancer Res. 2017 Oct 1;23(19):5679-5686. doi: 10.1158/1078-0432.CCR-17-0944.

3.

Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence.

van den Hout MFCM, Koster BD, Sluijter BJR, Molenkamp BG, van de Ven R, van den Eertwegh AJM, Scheper RJ, van Leeuwen PAM, van den Tol MP, de Gruijl TD.

Cancer Immunol Res. 2017 Nov;5(11):969-977. doi: 10.1158/2326-6066.CIR-17-0110. Epub 2017 Sep 21.

4.

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.

van den Hout MF, Sluijter BJ, Santegoets SJ, van Leeuwen PA, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Immunother. 2016 Apr;65(4):405-15. doi: 10.1007/s00262-016-1811-z. Epub 2016 Mar 2.

5.

Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.

Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Res. 2015 May;3(5):495-505. doi: 10.1158/2326-6066.CIR-14-0165. Epub 2015 Jan 29.

6.

Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation.

van de Ven R, van den Hout MF, Lindenberg JJ, Sluijter BJ, van Leeuwen PA, Lougheed SM, Meijer S, van den Tol MP, Scheper RJ, de Gruijl TD.

Blood. 2011 Sep 1;118(9):2502-10. doi: 10.1182/blood-2011-03-344838. Epub 2011 Jul 12.

PMID:
21750314
7.

The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma.

Oosterhoff D, Sluijter BJ, Hangalapura BN, de Gruijl TD.

Curr Top Microbiol Immunol. 2012;351:181-220. doi: 10.1007/82_2011_136. Review.

PMID:
21681685
8.

4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.

Sluijter BJ, van den Hout MF, Stam AG, Lougheed SM, Suhoski MM, van den Eertwegh AJ, van den Tol MP, van Leeuwen PA, Meijer S, Scheper RJ, June CH, de Gruijl TD, Santegoets SJ.

Clin Immunol. 2010 Nov;137(2):221-33. doi: 10.1016/j.clim.2010.07.009. Epub 2010 Aug 13.

PMID:
20708974
9.

Absence of Granzyme B positive tumour-infiltrating lymphocytes in primary melanoma excisional biopsies is strongly associated with the presence of sentinel lymph node metastasis.

van Houdt IS, Sluijter BJ, van Leeuwen PA, Moesbergen LM, Hooijberg E, Meijer CJ, de Gruijl TD, Oudejans JJ, Boven E.

Cell Oncol. 2009;31(5):407-13. doi: 10.3233/CLO-2009-0485.

10.

[Low prognostic importance of non-radical melanoma excision and the presence of melanoma cells in the re-excision specimen to overall and disease-free survival of melanoma patients].

Molenkamp BG, Sluijter BJ, Oosterhof B, Meijer S, Van Leeuwen PA.

Ned Tijdschr Geneeskd. 2008 Oct 18;152(42):2288-93. Dutch.

PMID:
19009879
11.

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.

Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Clin Cancer Res. 2008 Jul 15;14(14):4532-42. doi: 10.1158/1078-0432.CCR-07-4711.

12.

Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.

van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJ, Hooijberg E, van Leeuwen PA, Meijer CJ, Oudejans JJ.

Int J Cancer. 2008 Aug 1;123(3):609-15. doi: 10.1002/ijc.23543.

13.

Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.

Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Clin Cancer Res. 2007 May 15;13(10):2961-9.

14.

Non-radical diagnostic biopsies do not negatively influence melanoma patient survival.

Molenkamp BG, Sluijter BJ, Oosterhof B, Meijer S, van Leeuwen PA.

Ann Surg Oncol. 2007 Apr;14(4):1424-30. Epub 2007 Jan 17.

15.

Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option.

Molenkamp BG, van Leeuwen PA, van den Eertwegh AJ, Sluijter BJ, Scheper RJ, Meijer S, de Gruijl TD.

Immunobiology. 2006;211(6-8):651-61. Epub 2006 Jul 28. Review.

PMID:
16920504
16.

Aortic aneurysm repair is associated with a lower inflammatory response compared with surgery for inflammatory bowel disease.

Oldenburg HS, Siroen MP, Boelens PG, Sluijter BJ, Pruitt JH, Naseri AH, Rauwerda JA, Meijer S, Cuesta MA, van Leeuwen PA, Moldawer LL.

Eur Surg Res. 2004 Sep-Oct;36(5):266-73.

PMID:
15359089

Supplemental Content

Loading ...
Support Center